骨髓增生异常综合征分子国际预后评分系统的评估与验证
该研究回顾性分析了Moffitt癌症中心2355例骨髓增生异常综合征(MDS)患者的临床、细胞遗传学和分子数据,验证分子国际预后评分系统(IPSS-M)的预后准确性。IPSS-M将患者分为极低危(4%)、低危(24%)、中低危(14%)、中高危(11%)、高危(19%)和极高危(28%),中位总生存期从极低危的11.7年降至极高危的1.3年,中位无白血病生存期从12.3年降至0.5年。在治疗相关性和低增生性MDS中,该模型保留了预后准确性。
要点
- IPSS-M在2355例MDS患者中验证,中位总生存期从极低危11.7年降至极高危1.3年。
- 中位无白血病生存期从极低危12.3年降至极高危0.5年。
- 在治疗相关性和低增生性MDS中,IPSS-M保留了预后准确性。
核心结论
- IPSS-M在大型MDS队列中验证,保留预后准确性,包括治疗相关性和低增生性MDS。
- 广泛使用该工具可能实现更准确的预后评估并优化治疗决策。
研究设计与样本
- 回顾性研究,纳入Moffitt癌症中心治疗的2355例MDS患者。
- 分析临床、细胞遗传学和分子数据,评估IPSS-M与IPSS-R对无白血病生存期、总生存期和白血病转化的预测。
主要发现
- IPSS-M风险分组:极低危4%、低危24%、中低危14%、中高危11%、高危19%、极高危28%。
- 中位总生存期从极低危到极高危分别为11.7、7.1、4.4、3.1、2.3和1.3年。
- 中位无白血病生存期从极低危到极高危分别为12.3、6.9、3.6、2.2、1.4和0.5年。
- 在治疗相关性和低增生性MDS患者中,模型保留了预后准确性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Molecular International Prognostic Scoring System (IPSS-M) is a novel risk stratification model for myelodysplastic syndromes (MDS) that builds on the IPSS and IPSS-R by incorporating mutational data. The model showed improved prognostic accuracy over the IPSS-R across three endpoints: overall survival (OS), leukemia-free survival (LFS) and leukemic transformation. This study aimed to validate the findings of the original in a large cohort of MDS patients, as well as assess its validity in therapy-related and hypoplastic MDS. We retrospectively reviewed clinical, cytogenetic and molecular data for 2355 MDS patients treated at the Moffitt Cancer Center. Correlative analysis between IPSS-R and mean IPSS-M scores and outcome predictions was performed on LFS, OS and leukemic transformation. Using the IPSS-M, patients were classified as Very Low (4%), Low (24%), Moderate-Low (14%), Moderate-High (11%), High (19%) and Very-High risk (28%). Median OS was 11.7, 7.1, 4.4, 3.1, 2.3, and 1.3 years from VL to VH risk subgroups. Median LFS was 12.3, 6.9, 3.6, 2.2, 1.4, and 0.5 years respectively. For patients with t-MDS and h-MDS the model retained its prognostic accuracy. Generalized use of this tool will likely result in more accurate prognostic assessment and optimize therapeutic decision-making in MDS.
引用
- Aguirre LE, Al Ali N, Sallman DA, et al. Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes. Leukemia. 2023. PMID: 37147425. doi:10.1038/s41375-023-01910-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。